

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Michael KARAS *et al.*

Serial No.: 10/790,768

Filed: March 3, 2004

)  
)  
)  
)  
)  
)

Group Art No. 1646

Examiner: TBA

Docket No: 002877.00028

For: INTRACELLULAR DELIVERY OF SMALL MOLECULES,  
PROTEINS, AND NUCLEIC ACIDS

**SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

U.S. Patent and Trademark Office  
Customer Service Window, Mail Stop Amendment  
Randolph Building  
401 Dulany Street  
Alexandria, VA 22314

Sir:

In accordance with 37 C.F.R. §§ 1.97 and 1.98, a Form PTO-1449 is attached, identifying information for the Examiner's consideration. Copies of the listed documents are enclosed.


We believe no fee is due in connection with this filing. If a fee is due, please charge our Deposit Account No. 19-0733.

Respectfully submitted,  
BANNER & WITCOFF, LTD.

Dated: March 4, 2005

By: Lisa M. Hemmendinger  
Lisa M. Hemmendinger  
Reg. No. 42,653

Customer No. 22907



PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 1

**Complete if Known**

Application Number	10/790,768
Filing Date	March 3, 2004
First Named Inventor	Michael KARAS
Art Unit	1646
Examiner Name	TBA
Attorney Docket Number	002877.00028

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		DIETZ ET AL., "Inhibition of Neuronal Apoptosis <i>in Vitro</i> and <i>in Vivo</i> Using TAT-Mediated Protein Transduction", <i>Molecular and Cellular Neuroscience</i> , 2002, pp 29-37, Vol. 21.	
		FAWALL ET AL., "Tat-mediated delivery of heterologous proteins into cells", Biogen Inc., October 7, 1993, pp. 664-668.	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.